Category

Archives

Axl

Growth Arrest-Specific Factor 6 (GAS6) Is Increased in COVID-19 Patients and Predicts Clinical Outcome

3 views | Jul 01 2021

Albert Morales et al. thought that plasma GAS6 and AXL levels reflected COVID-19 severity and could be early markers of disease prognosis, supporting a relevant role of the GAS6/AXL system in the immune response in COVID-19. [Read the Full Post]

AXL receptor tyrosine kinase: a possible therapeutic target in acute promyelocytic leukemia

4 views | Jul 01 2021

Mariam Fatima et al. suggested targeting of AXL-RTK in the treatment of therapy resistant APL patients. [Read the Full Post]

Impact of tumor growth rate during preceding treatment on tumor response to nivolumab or irinotecan in advanced gastric cancer

8 views | Jun 15 2021

K Kato et al. suggested that NIVO treatment was a more favorable option for patients with slow-growing tumors, and NIVO and IRI were similarly recommended for patients with rapid-growing tumors in refractory AGC. TGR and NL emergence during preceding treatment might be helpful for drug selection and warrant further investigation. [Read the Full Post]

Soyasaponin A 2 Alleviates Steatohepatitis Possibly through Regulating Bile Acids and Gut Microbiota in the Methionine and Choline Deficient (MCD) Diet-induced Non-alcoholic Steatohepatitis (NASH) Mice

8 views | Jun 09 2021

Fei Xiong et al. found that SS-A2 alleviated steatohepatitis possibly through regulating BAs and gut microbiota in the MCD diet-induced NASH mice. [Read the Full Post]

Pathological significance of abnormal recepteur d'origine nantais and programmed death ligand 1 expression in colorectal cancer

28 views | Jan 19 2021

Yi-Zhi Liu et al. found that RON, PD-L1, and their crosstalk were significant in predicting the prognostic value of CRC. [Read the Full Post]

FLT3 inhibitors in the treatment of Acute Myeloid Leukemia: current status and future perspectives

51 views | Oct 20 2020

Adrián Mosquera Orgueira et al.focused on the role of FLT3 mutations in AML, pharmacological features of FLT3 inhibitors, known mechanisms of drug resistance and accumulated evidence for the use of FLT3 inhibitors in different clinical settings. [Read the Full Post]